Tag: Alnylam Amvuttra


NICE backs Alnylam’s Amvuttra for rare form of amyloidosis

January 19, 2023

Via: Pharmaphorum

Amvuttra (vutrisiran) is a follow-up to Alnylam’s earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler, more patient-friendly dosing regimen. The new therapy is given as […]